Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Fundamental Analysis
Translational Development Acquisition Corp. (TDACU) shows weak financial fundamentals with a PE ratio of 29.57, profit margin of 0.00%, and ROE of 3.57%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 23.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze TDACU's fundamental strength across five key dimensions:
Efficiency Score
WeakTDACU struggles to generate sufficient returns from assets.
Valuation Score
ModerateTDACU shows balanced valuation metrics.
Growth Score
ModerateTDACU shows steady but slowing expansion.
Financial Health Score
ModerateTDACU shows balanced financial health with some risks.
Profitability Score
WeakTDACU struggles to sustain strong margins.
Key Financial Metrics
Is TDACU Expensive or Cheap?
P/E Ratio
TDACU trades at 29.57 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, TDACU's PEG of -1.73 indicates potential undervaluation.
Price to Book
The market values Translational Development Acquisition Corp. at 1.04 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -265.11 times EBITDA. This is generally considered low.
How Well Does TDACU Make Money?
Net Profit Margin
For every $100 in sales, Translational Development Acquisition Corp. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.57 in profit for every $100 of shareholder equity.
ROA
Translational Development Acquisition Corp. generates $3.39 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.04 in free cash annually.
FCF Yield
TDACU converts -0.29% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.57
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.73
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.04
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.003
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.00
vs 25 benchmark
How TDACU Stacks Against Its Sector Peers
| Metric | TDACU Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.57 | 19.08 | Worse (Expensive) |
| ROE | 3.57% | 799.00% | Weak |
| Net Margin | 0.00% | -7710.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 2.40 | Strong (Low Leverage) |
| Current Ratio | 0.09 | 560.55 | Weak Liquidity |
| ROA | 3.39% | -23972.00% (disorted) | Weak |
TDACU outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Translational Development Acquisition Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Value, Dividend, Cyclical
DecliningEPS CAGR
-0.50%
Industry Style: Value, Dividend, Cyclical
DecliningFCF CAGR
-587104.14%
Industry Style: Value, Dividend, Cyclical
Declining